SAN DIEGO--(EON: Enhanced Online News)--Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Jonathan Seaton as Senior Vice President for Corporate & Business Development, further strengthening its executive team as the company continues reinforcing the foundation for long-term growth. Jonathan will join Illumina on January 3, 2017.
“The proven critical thinking he brings to Illumina coupled with his comprehensive understanding of the markets we address make him a great addition to our executive team.”
“Jonathan is a strong leader with an established track record of successful strategic planning and business development in the clinical and life sciences space,” said Marc Stapley, Executive Vice President and Chief Administrative Officer of Illumina. “The proven critical thinking he brings to Illumina coupled with his comprehensive understanding of the markets we address make him a great addition to our executive team.”
Jonathan will be responsible for global business development activities, including strategic commercial deals, mergers and acquisitions, licensing and partnerships. He joins Illumina from Becton, Dickinson and Company where he was Vice President and Head of Strategy and Business Development for the Life Sciences segment. He previously held leadership roles at F. Hoffman-La Roche, Roche Tissue Diagnostics, LS9, and several consulting firms and investment banks. Jonathan studied medicine at the University of Manchester, received a BSc degree in Molecular Biology and Biochemistry from the University of Durham, and an MBA from the Saïd Business School at the University of Oxford.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services, and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.